Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the United States.

William J ValentineMeredith HoogReema R ModyMark BelgerRichard F Pollock

Published in: Diabetes, obesity & metabolism (2023)

Long-term projections based on the SURPASS-2 trial results indicate that 5, 10 and 15 mg doses of tirzepatide are likely to be cost-effective versus semaglutide 1.0 mg for the treatment of type 2 diabetes in the United States.

Keyphrases

clinical trial
phase iii
randomized controlled trial
phase ii
open label
replacement therapy
placebo controlled